Credit: Tarsus Pharmaceuticals. Xdemvy is supplied as an ophthalmic solution containing lotilaner 0.25% (2.5mg/mL) in a 10mL bottle; it is expected to be available by the end of August 2023. The Food ...

An overview of the current landscape of available treatment options for Demodex blepharitis is analyzed. This is a video synopsis/summary of a discussion involving Elizabeth Yeu, MD. Yeu discusses how ...

Eric D. Donnenfeld, MD; underscores the significance of an FDA approved treatment for Demodex blepharitis as well as past alternative treatments. This is a video synopsis/summary of an Insights ...

Demodex blepharitis may affect up to 25 million Americans and result in significant clinical, functional and psychosocial burden for patients Saturn-2 trial design similar to Saturn-1, first pivotal ...

Unique and memorable campaign intended to educate consumers about Demodex blepharitis and XDEMVY, the first and only FDA approved solution for the disease Demodex blepharitis impacts approximately 25 ...

The FDA approved lotilaner ophthalmic solution 0.25% (Xdemvy) as the first specific treatment for Demodex blepharitis. Lotilaner (formerly TP-03) is an ectoparasiticide that targets Demodex mites, ...

Please provide your email address to receive an email when new articles are posted on . Demodex blepharitis is so common that it makes up more than two thirds of all blepharitis cases. In fact, nearly ...

Welcome to the Mite Party. In its latest effort to raise awareness about demodex blepharitis, an eye condition that affects 25 million Americans, Tarsus Pharmaceuticals is throwing a party — a Mite ...

XDEMVY is the first and only approved therapeutic for Demodex blepharitis, a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. XDEMVY targets the root ...

(RTTNews) - Tarsus Pharmaceuticals, Inc. (TARS) announced the FDA approved XDEMVY 0.25% for the treatment of Demodex blepharitis. XDEMVY is the first and only FDA approved treatment to directly target ...

IRVINE, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...

Waking up with some gunk in your eyes is usually nothing to worry about. The scientific name for this crust is rheum, and it forms when oil and other debris collect on your eyelids during sleep. But ...